Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neurop...( STAMFORD Conn Nov. ...),Health

STAMFORD, Conn, Nov. 20 /PRNewswire/ -- Purdue Pharma L.P. and Mundipharma International Corporation Limited, today announced that they have entered into a global strategic alliance with Infinity Pharmaceuticals, Inc. to advance the research, development, and commercialization of Infinity's discovery and early clinical programs in the areas of oncology and neuropathic pain.

The alliance will focus on supporting Infinity's pipeline of novel, small molecule oncology drug candidates, including IPI-926, a potent inhibitor of the Hedgehog pathway, which is being evaluated in a Phase 1 clinical study in patients with advanced solid tumors. IPI-926 has demonstrated significant anti-tumor activity in a number of preclinical models. Infinity will direct and lead oncology discovery and development efforts on a worldwide basis. Under the terms of the agreements, Infinity will retain United States commercialization rights for all oncology products developed under these programs and will pay Mundipharma a royalty on U.S. sales. Mundipharma has the right to commercialize these products outside of the United States, and will pay a royalty to Infinity on sales outside of the United States.

Under a separate agreement, Purdue's associated company, Purdue Pharmaceutical Products L.P., and Mundipharma will have the worldwide rights to assume development of Infinity's fatty acid amide hydrolase (FAAH) program, an experimental target for the treatment of neuropathic pain, at the conclusion of Phase 1 clinical studies. Infinity's FAAH inhibitor program is in lead optimization and the company expects to select a clinical candidate by early 2009. Purdue and Mundipharma will fund all research and development costs of the program through regulatory approval, and will pay a royalty to Infinity on global net sales of any products commercialized.

"Purdue U.S., Purdue Canada, and Mundipharma
'/>"/>